MCID: PLS007
MIFTS: 57

Plasmodium Falciparum Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Falciparum Malaria

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 15
Malaria, Falciparum 44 73
Falciparum Malaria 12 15
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Malaria Falciparum 55

Classifications:



External Ids:

Disease Ontology 12 DOID:14067
ICD10 33 B50 B50.9 B50.0
ICD9CM 35 084.0
MeSH 44 D016778
NCIt 50 C34798
SNOMED-CT 68 62676009
UMLS 73 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to hepatitis a and schistosomiasis. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are hematopoietic system and cellular

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 30.7 IFNG IL10 TNF
2 schistosomiasis 30.6 IFNG IL10 TNF
3 q fever 30.5 IFNG IL10 TNF
4 sickle cell anemia 30.4 G6PD HBB TNF
5 bacterial sepsis 30.4 IL10 SELE TNF
6 pulmonary edema 30.3 ICAM1 IL10 TNF
7 brucellosis 30.3 IFNG IL10 IL18 TNF
8 malaria 30.3 CD36 CD55 CHIT1 CR1 DHFR FCGR2A
9 leptospirosis 30.2 IFNG IL10 TNF
10 plasmodium vivax malaria 30.1 G6PD ICAM1 IFNG IL10 SELE TNF
11 hemolytic anemia 30.1 CD55 G6PD HBB HP
12 human immunodeficiency virus infectious disease 30.0 IFNG IL10 TLR9 TNF
13 glucosephosphate dehydrogenase deficiency 30.0 G6PD HBB HP
14 dengue hemorrhagic fever 30.0 FCGR2A IFNG IL10 TNF
15 hemophagocytic lymphohistiocytosis 29.9 CR1 IFNG IL10 IL18 TNF
16 meningitis 29.9 FCGR2A IFNG IL10 TLR9 TNF
17 glomerulonephritis 29.8 CR1 ICAM1 MIF TLR9
18 alpha-thalassemia 29.7 G6PD HBB HP
19 dermatitis, atopic 29.5 ICAM1 IFNG IL10 IL18 SELE TLR9
20 asthma 29.4 CHIT1 ICAM1 IFNG IL10 IL18 SELE
21 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.5
22 ovalocytosis, southeast asian 11.3
23 pemphigus foliaceus 10.5
24 lymphoma 10.5
25 rothmund-thomson syndrome 10.4
26 hepatitis 10.4
27 thrombocytopenia 10.4
28 burkitt lymphoma 10.3
29 aceruloplasminemia 10.3
30 transient hypogammaglobulinemia 10.3 IL10 TNF
31 nickel allergic contact dermatitis 10.3 IFNG IL10
32 sporotrichosis 10.3 IFNG IL10
33 trichosporonosis 10.3 IFNG TNF
34 chronic beryllium disease 10.3 IFNG TNF
35 farmer's lung 10.3 CD36 TNF
36 necrotizing ulcerative gingivitis 10.3 IL10 IL18
37 punctate inner choroidopathy 10.3 IL10 TNF
38 tropical endomyocardial fibrosis 10.3 IL10 TNF
39 endomyocardial fibrosis 10.3 IL10 TNF
40 adult respiratory distress syndrome 10.3
41 hepatitis b 10.3
42 cholecystitis 10.3
43 iron metabolism disease 10.3
44 acalculous cholecystitis 10.3
45 acute respiratory distress syndrome 10.3
46 encephalopathy 10.3
47 critical limb ischemia 10.2 SELE TNF
48 cephalosporin allergy 10.2 IFNG IL10
49 african tick-bite fever 10.2 IFNG SELE
50 interstitial lung disease 10.2 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CD36 CD55 DHFR FCGR2A G6PD HP
2 cellular MP:0005384 10.27 CD36 DHFR G6PD HP ICAM1 IFNG
3 cardiovascular system MP:0005385 10.22 CD36 DHFR G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.18 CD36 DHFR G6PD HP ICAM1 IFNG
5 immune system MP:0005387 10.17 CD36 CD55 CHIT1 DHFR FCGR2A HP
6 digestive/alimentary MP:0005381 9.98 CD36 ICAM1 IFNG IL10 IL18 TLR9
7 mortality/aging MP:0010768 9.97 CD36 DHFR FCGR2A G6PD HP ICAM1
8 liver/biliary system MP:0005370 9.8 CD36 DHFR HP IFNG IL10 SELE
9 muscle MP:0005369 9.56 CD36 DHFR ICAM1 IFNG IL10 IL18
10 neoplasm MP:0002006 9.1 HP ICAM1 IFNG IL10 MIF TNF

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71963-77-4 119380 68911
3
Mefloquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53230-10-7 4046
4
Artesunate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 88495-63-0 5464098 6917864
5
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Sulfadoxine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2447-57-6 17134
9
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
10
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
11
Nevirapine Approved Phase 4,Early Phase 1 129618-40-2 4463
12
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-05-7 2719
13
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
14
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 500-92-5 4923
15
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 95233-18-4 74989
16
Quinine Approved Phase 4,Phase 3,Phase 2,Not Applicable 130-95-0 3034034 8549
17
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
19
Lactitol Investigational Phase 4,Phase 3,Phase 1,Not Applicable 585-86-4 3871
20
Dihydroartemisinin Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
21
Piperaquine Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4085-31-8 5079497
22
Chlorproguanil Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 537-21-3 151170 9571037
23
Pyronaridine Investigational Phase 4,Phase 3,Phase 2 74847-35-1 5485198
24 Artemisinins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antimalarials Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Artemisinine Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Amodiaquine, artesunate drug combination Phase 4,Not Applicable
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Infective Agents, Urinary Phase 4,Phase 2,Phase 3,Not Applicable
40 Fanasil, pyrimethamine drug combination Phase 4,Phase 2,Phase 3,Not Applicable
41 Renal Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Chloroquine diphosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-63-5
43 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Atovaquone, proguanil drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 326)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
2 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
3 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
4 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
5 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
6 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
7 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
8 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
9 Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
10 Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
11 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
12 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
13 Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
14 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
15 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
16 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
17 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
18 Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
19 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
20 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4 Coarsucam;Coartem
21 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4 artesunate and mefloquine
22 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4 Chloroquine
23 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
24 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
25 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4 AQAS
26 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
27 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
28 Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
29 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
30 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
31 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
32 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
33 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
34 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
35 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4 Co-artemether
36 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
37 Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
38 Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
39 In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy Completed NCT01976780 Phase 4 Artesunate;Artemether Lumefantrine;Mefloquine
40 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
41 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
42 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4 Artesunate-Amodiaquine
43 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4 artesunate;quinine
44 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4 Arterakin (DHA-PPQ)
45 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4 Amodiaquine-Artesunate;Artemether-lumefantrine
46 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
47 In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children Completed NCT02168569 Phase 4 Coartem™ (Artemether-lumefantrine combination);Coarsucam™ (Amodiaquine-artesunate combination)
48 Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Completed NCT01998295 Phase 4 Artemether/lumefantrine
49 Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy Completed NCT00495508 Phase 4 Quinine;artemether / lumefantrine
50 In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Completed NCT00144352 Phase 4 sulfadoxine-pyrimethamine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

41
Testes, T Cells, Liver, Skin, B Cells, Eye, Endothelial

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 1079)
# Title Authors Year
1
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
2
Severe Plasmodium falciparum Malaria Treated With Investigational Artesunate in the United States. ( 29898630 )
2018
3
Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. ( 29534720 )
2018
4
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
5
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria. ( 29909070 )
2018
6
Etiology of Placental Plasmodium falciparum Malaria in African Women. ( 29579263 )
2018
7
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India. ( 29842979 )
2018
8
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
9
Can the Therapeutically-rational Exchange (T-REX) of Glucose-6-phosphate Dehydrogenase Deficient Red Blood Cells Reduce Plasmodium falciparum Malaria Morbidity and Mortality? ( 29717302 )
2018
10
Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across CA'te da89Ivore ( 29717574 )
2018
11
Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia. ( 29980936 )
2018
12
Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. ( 29764419 )
2018
13
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. ( 29615039 )
2018
14
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria. ( 29220497 )
2018
15
Sub-acute intestinal obstruction - a rare complication of Plasmodium falciparum malaria in an adult: a case report. ( 29966528 )
2018
16
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. ( 29703425 )
2018
17
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( 29347975 )
2018
18
Plasmodium falciparum malaria skews globin gene expression balance in in-vitro haematopoietic stem cell culture system: Its implications in malaria associated anemia. ( 29309785 )
2018
19
Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. ( 29883485 )
2018
20
Epidemiological, Clinical, and Laboratory Evaluation of Plasmodium falciparum Malaria Cases Followed in Firat University Hospital: A 6-Year Retrospective Analysis. ( 29780012 )
2018
21
Mild encephalitis/encephalopathy with a reversible splenial lesion due to Plasmodium falciparum malaria: a case report. ( 30410417 )
2018
22
Can Therapeutically-Rational Exchange (T-REX) of Thalassemic Red Blood Cells Improve the Clinical Course of Plasmodium falciparum Malaria? ( 30515048 )
2018
23
Evaluation of PTA-derived ruthenium(II) and iridium(III) quinoline complexes against chloroquine-sensitive and resistant strains of the Plasmodium falciparum malaria parasite. ( 30529881 )
2018
24
Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa? ( 30547849 )
2018
25
Inducing controlled cell cycle arrest and re-entry during asexual proliferation of Plasmodium falciparum malaria parasites. ( 30409996 )
2018
26
Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India. ( 30428283 )
2018
27
A Cross-Sectional Population Study of Geographic, Age-Specific, and Household Risk-Factors for Asymptomatic Plasmodium falciparum Malaria Infection in Western Kenya. ( 30457091 )
2018
28
Can malaria rapid diagnostic tests by drug sellers under field conditions classify children 5 years old or less with or without Plasmodium falciparum malaria? Comparison with nested PCR analysis. ( 30326926 )
2018
29
Cryptic severe Plasmodium falciparum malaria in a Moroccan man living in Tuscany, Italy, August 2018. ( 30326993 )
2018
30
An investigation of the Plasmodium falciparum malaria epidemic in Kavango and Zambezi regions of Namibia in 2016. ( 30252108 )
2018
31
Projecting potential spatial and temporal changes in the distribution of Plasmodium vivax and Plasmodium falciparum malaria in China with climate change. ( 30283159 )
2018
32
A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. ( 30290808 )
2018
33
Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border. ( 30176888 )
2018
34
Correction: Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. ( 30222763 )
2018
35
Failure of intravenous artesunate treatment for Plasmodium falciparum malaria in a splenectomized traveller: A diagnostic challenge. ( 30227244 )
2018
36
A Case of Recrudescence Plasmodium falciparum Malaria Treated with Atovaquone-Proguanil. ( 30072357 )
2018
37
Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. ( 30077118 )
2018
38
Complement Factor H Levels Associate With Plasmodium falciparum Malaria Susceptibility and Severity. ( 30087905 )
2018
39
Correction to: Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities in Kinshasa Province, Democratic Republic of the Congo. ( 30089480 )
2018
40
Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children. ( 30105967 )
2018
41
Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal. ( 30123520 )
2018
42
Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. ( 30150462 )
2018
43
Exploring pancreatic pathology in Plasmodium falciparum malaria patients. ( 29993021 )
2018
44
Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission. ( 30002917 )
2018
45
Case Report: A Cluster of Plasmodium falciparum Malaria Cases among Thai Workers in Gembu, Nigeria. ( 30014824 )
2018
46
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. ( 30061282 )
2018
47
Plasmodium falciparum malaria cases detected for prompt treatment by rapid diagnostic tests in the Ho Teaching Hospital of the Volta Region of Ghana. ( 29988323 )
2018
48
Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants. ( 29061746 )
2018
49
To prevent or ameliorate severe Plasmodium falciparum malaria, why not evaluate the impact of exchange transfusions of sickle cell trait red blood cells? ( 29310873 )
2018
50
Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. ( 29398389 )
2018

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Show member pathways
12.83 CD55 ICAM1 IFNG IL10 IL18 TNF
3
Show member pathways
12.73 ICAM1 IFNG IL18 TLR9 TNF
4
Show member pathways
12.29 DHFR HBB ICAM1 IFNG TNF
5
Show member pathways
12.18 CR1 FCGR2A IFNG IL10 TNF
6 12.06 ICAM1 IFNG SELE TNF
7 12.05 CR1 FCGR2A IFNG IL10 IL18 TLR9
8
Show member pathways
12.01 CD36 FCGR2A IFNG TNF
9
Show member pathways
11.99 IFNG IL10 IL18 TLR9 TNF
10 11.93 FCGR2A ICAM1 IFNG MIF TNF
11 11.9 CD36 FCGR2A IFNG IL10 TNF
12 11.88 ICAM1 SELE TNF
13
Show member pathways
11.86 CD36 HBB HP
14 11.86 CD36 CD55 CR1 TNF
15 11.86 CD36 ICAM1 IL10 IL18 TNF
16 11.83 ICAM1 SELE TNF
17 11.82 ICAM1 IFNG IL18 TNF
18 11.81 IFNG IL10 TNF
19 11.76 CR1 FCGR2A TLR9
20 11.75 IFNG IL10 IL18 TNF
21 11.74 ICAM1 IFNG SELE
22 11.71 IFNG IL10 TLR9 TNF
23 11.56 FCGR2A ICAM1 IL10
24 11.55 CR1 IL18 TNF
25
Show member pathways
11.52 ICAM1 IFNG MIF SELE TNF
26 11.49 HP ICAM1 TNF
27 11.49 ICAM1 IL10 IL18 TNF
28 11.48 IFNG IL18 TNF
29 11.48 CD36 FCGR2A IFNG IL10 IL18 TNF
30 11.34 CD36 CR1 HBB ICAM1 IFNG IL10
31 11.28 IFNG IL18 TNF
32 11.23 IFNG IL10 TNF
33 11.16 ICAM1 IFNG IL18
34 10.9 CD36 ICAM1 TNF
35 10.77 HBB ICAM1 IFNG IL10 IL18 SELE

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD55 CHIT1 HBB HP IFNG IL10
2 cell surface GO:0009986 9.73 CD36 CD55 CR1 ICAM1 MIF TNF
3 secretory granule membrane GO:0030667 9.58 CD55 CR1 FCGR2A
4 tertiary granule lumen GO:1904724 9.5 CHIT1 HBB HP
5 endocytic vesicle lumen GO:0071682 9.46 HBB HP
6 haptoglobin-hemoglobin complex GO:0031838 9.37 HBB HP
7 extracellular space GO:0005615 9.36 CD36 CHIT1 HBB HP ICAM1 IFNG
8 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
9 extracellular exosome GO:0070062 10.03 CD55 CR1 G6PD HBB HP ICAM1

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 CD36 IFNG MIF TNF
2 defense response to bacterium GO:0042742 9.97 HP IL10 TLR9 TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CD36 ICAM1 MIF TNF
4 leukocyte migration GO:0050900 9.93 ICAM1 MIF SELE TNF
5 cytokine-mediated signaling pathway GO:0019221 9.91 CD36 ICAM1 IL10 IL18 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.87 CD36 ICAM1 IL10 TNF
7 response to organic substance GO:0010033 9.86 HP IL10 TNF
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 CD36 ICAM1 MIF
9 viral entry into host cell GO:0046718 9.85 CD55 CR1 ICAM1
10 inflammatory response GO:0006954 9.85 IL10 IL18 MIF SELE TLR9 TNF
11 positive regulation of inflammatory response GO:0050729 9.84 IL18 TLR9 TNF
12 positive regulation of interleukin-6 production GO:0032755 9.81 CD36 TLR9 TNF
13 response to hydrogen peroxide GO:0042542 9.78 HBB HP MB
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.77 IL18 TLR9 TNF
15 positive regulation of tumor necrosis factor production GO:0032760 9.77 CD36 MIF TLR9
16 positive regulation of cell death GO:0010942 9.75 CD36 HBB HP
17 interleukin-12-mediated signaling pathway GO:0035722 9.73 IFNG IL10 MIF
18 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.7 CD36 IL18
19 oxygen transport GO:0015671 9.7 HBB MB
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IFNG TNF
21 immune response GO:0006955 9.7 CD36 CHIT1 IFNG IL10 IL18 TLR9
22 regulation of regulatory T cell differentiation GO:0045589 9.69 CR1 IFNG
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL10 TNF
24 response to molecule of bacterial origin GO:0002237 9.68 IL10 TLR9
25 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.68 IL18 TLR9
26 negative regulation of interleukin-6 production GO:0032715 9.67 IL10 TLR9 TNF
27 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.66 TLR9 TNF
28 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
29 negative regulation of interleukin-8 production GO:0032717 9.65 IL10 TLR9
30 positive regulation of cytokine secretion GO:0050715 9.65 IL10 MIF TNF
31 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.65 CD36 ICAM1 IL18 TLR9 TNF
32 regulation of removal of superoxide radicals GO:2000121 9.64 CD36 DHFR
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 ICAM1 TNF
35 positive regulation of neuroinflammatory response GO:0150078 9.61 IL18 TNF
36 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.58 MIF TNF
37 positive regulation of interleukin-12 production GO:0032735 9.58 CD36 IFNG TLR9
38 neutrophil degranulation GO:0043312 9.56 CD36 CD55 CHIT1 CR1 FCGR2A HBB
39 type 2 immune response GO:0042092 9.55 IL10 IL18
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 IFNG TNF
41 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
42 negative regulation of growth of symbiont in host GO:0044130 9.5 CD36 IL10 TNF
43 positive regulation of blood microparticle formation GO:2000334 9.46 CD36 TNF
44 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
45 positive regulation of nitric oxide biosynthetic process GO:0045429 9.02 CD36 HBB ICAM1 IFNG TNF
46 regulation of signaling receptor activity GO:0010469 10.05 IFNG IL10 IL18 MIF TNF
47 positive regulation of gene expression GO:0010628 10.03 CD36 IFNG IL18 TLR9 TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 CD55 CR1 ICAM1
2 oxygen carrier activity GO:0005344 9.26 HBB MB
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
4 hemoglobin binding GO:0030492 8.96 HBB HP

Sources for Plasmodium Falciparum Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....